Pharmaceutical Technology
The FDA has approved Daiichi Sankyo and AstraZeneca’s Enhertu for two new indications in HER2-positive early breast cancer.
Pharmaceutical Technology
The FDA has approved Daiichi Sankyo and AstraZeneca's Enhertu for two new indications in HER2-positive early breast cancer.
Pharmaceutical Technology
The FDA has approved Daiichi Sankyo and AstraZeneca’s Enhertu for two new indications in HER2-positive early breast cancer.